CClinicalTrials.gg
CompletedNCT06039228Updated Apr 17, 2026

School-based Group Acceptance and Commitment Therapy for Adolescents

An interventional study of Acceptance and commitment therapy in Depressive Symptoms, Anxiety and Stress, sponsored by Chinese University of Hong Kong. Completed at 1 site in Hong Kong. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
12 Years to 18 Years
Sex
All
01

Study summary

The objective of the investigators' mental health promotion intervention premised on the Acceptance and Commitment Therapy (ACT) framework in secondary school settings aims to enhance young people's psychological flexibility and reduce their emotional distress. ACT is an evidence-based approach that encourages individuals to act in alignment with their identified values. The investigator's team will employ an ACT protocol for adolescents developed by Louise Hayes and Joseph Ciarrochi. The study includes a single-group study design. The investigator will compare the pre- and post-intervention data to assess the feasibility and potential effectiveness of the group intervention.

02

Conditions studied

  • Depressive Symptoms
  • Anxiety
  • Stress
03

In context

Depression

8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.

This study's enrollment of 61 is below the median of 84 across 6,720 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Eligible participants are adolescents who reported mild to moderate severity of psychological distress, including those who report:

  • a score of 5-19 on the Patient Health Questionnaire (PHQ-9), or
  • a score of 5-14 on the General Anxiety Disorder-7, or
  • a score ≥14 on the Perceived Stress Scale.

Exclusion criteria

Exclusion Criteria:

Adolescents will be excluded if they exhibit or report:

  • violent or aggressive behavior, or
  • active self-injurious or suicidal thought, or
  • active psychotic symptom.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Intervention group

    Behavioral: Acceptance and commitment therapy

Interventions

  • BehavioralAcceptance and commitment therapy

    Four sessions of group acceptance and commitment therapy, with each session lasting for 1.5 hours.

06

What researchers measure

Primary outcomes

  1. Acceptance and Action Questionnaire - II

    Time frame: Baseline and 4 weeks

  2. The 14-item Resilience Scale

    Time frame: Baseline and 4 weeks

  3. Patient Health Questionnaire - 9

    Time frame: Baseline and 4 weeks

  4. General Anxiety Disorder - 7

    Time frame: Baseline and 4 weeks

  5. Perceived Stress Scale

    Time frame: Baseline and 4 weeks

Secondary outcomes

  1. Satisfaction with Life Scale

    Time frame: Baseline and 4 weeks

  2. Pittsburgh Sleep Quality Index

    Time frame: Baseline and 4 weeks

07

Study locations

1 site
  • Department of Educational Psychology, The Chinese University of Hong Kong
    Shatin, Hong Kong
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06039228
Lead sponsor
Chinese University of Hong Kong
Responsible party
Jennifer Yee Man Tang (Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Sep 15, 2023
Start date
Jul 1, 2023
Primary completion
Jun 30, 2024
Completion
Aug 31, 2024
Last update
Apr 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion